TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy

Cancer Research

Volumn 73, Issue 24, 2013, Pages 7211-7221

  Gao, Chan ^a   Kozlowska, Anna ^a,b   Nechaev, Sergey ^a   Li, Haiqing ^a   Zhang, Qifang ^a   Hossain, Dewan M S ^a   Kowolik, Claudia M ^a   Chu, Peiguo ^a   Swiderski, Piotr ^a   Diamond, Don J ^a   Pal, Sumanta K ^a   Raubitschek, Andrew ^a   Kortylewski, Marcin ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JANUS KINASE; MYELOID DIFFERENTIATION FACTOR 88; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BONE MARROW CELL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VASCULARIZATION; UPREGULATION; WILD TYPE;

ANIMALS; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERLEUKIN-6; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 9; TUMOR MICROENVIRONMENT; URINARY BLADDER NEOPLASMS;

EID: 84891277691     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1314     Document Type: Article

References (50)

1. Bernier J, Hall EJ, Giaccia A. Radiation oncology: A century of achievements. Nat Rev Cancer 2004;4:737-47.
2. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011;11:239-53.
3. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007;204:49-55.
4. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10:718-26.
5. Karar J, Maity A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther 2009;8:1994-2001.
6. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz- Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9.
7. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A 2010;107:8363-8.
8. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010;120: 694-705.
9. Kozin SV, Duda DG, Munn LL, Jain RK. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors J Natl Cancer Inst 2012;104:899-905.
10. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 2010;70:5679-85.
11. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-37.
12. Sansone P, Bromberg J. Environment, inflammation, and cancer. Curr Opin Genet Dev 2011;21:80-5.
13. Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury- and death-induced inflammation. Immunity 2011;35:467-77.
14. Goldszmid RS, Trinchieri G. The price of immunity. Nat Immunol 2012;13:932-8.
15. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008;8:279-89.
16. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012;12:860-75.
17. Roses RE, Xu M, Koski GK, Czerniecki BJ. Radiation therapy and Tolllike receptor signaling: Implications for the treatment of cancer. Oncogene 2008;27:200-7.
18. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7:179-90.
19. Murray PJ. NOD proteins: An intracellular pathogen-recognition system or signal transduction modifiers Curr Opin Immunol 2005;17: 352-8.
20. Murray PJ, Smale ST. Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. Nat Immunol 2012; 13:916-24.
21. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
22. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002;196:541-9.
23. Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y, et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 2009;69:2497-505.
24. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367-77.
25. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009;15:114-23.
26. Renan MJ, Dowman PI. Increased radioresistance of tumor cells exposed to metallothionein-inducing agents. Radiat Res 1989;120: 442-55.
27. Klinman DM, Gursel I, Klaschik S, Dong L, Currie D, Shirota H. Therapeutic potential of oligonucleotides expressing immunosuppressive TTAGGG motifs. Ann N Y Acad Sci 2005;1058: 87-95.
28. Weis SM, Cheresh DA. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70.
29. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
30. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010;11: 373-84.
31. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther 2012;22:77-89.
32. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
33. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21.
34. Bosco MC, Puppo M, Blengio F, Fraone T, Capello P, Giovarelli M, et al. Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. Immunobiology 2008;213:733-49.
35. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009;27:925-32.
36. Formenti SC,Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012;84:879-80.
37. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, et al. Caspase-3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011;17:860-6.
38. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010;464:104-7.
39. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012;485:251-5.
40. Shatz M, Menendez D, Resnick MA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res 2012;72:3948-57.
41. McKelvey KJ, Highton J, Hessian PA. Cell-specific expression of TLR9 isoforms in inflammation. J Autoimmun 2011;36:76-86.
42. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Liderau R, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancerchemotherapy and radiotherapy. NatMed2007;13:1050-9.
43. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8: 487-96.
44. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2009;21:11-9.
45. Klaschik S, Tross D, Klinman DM. Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J Leukoc Biol 2009;85:788-95.
46. Zabuawala T, Taffany DA, Sharma SM, Merchant A, Adair B, Srinivasan R, et al. An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res 2010;70: 1323-33.
47. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 2012;13:1118-28.
48. Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007; 21:1546-58.
49. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. J Clin Oncol 2010;28:4324-32.
50. Nechaev S, Gao C, Moreira D, Swiderski P, Jozwiak A, Kowolik CM, et al. Intracellular processing of immunostimulatory CpG-siRNA: Tolllike receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release 2013;170:307-15.